Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
1,578
archived clinical trials in
Skin and Soft Tissue Infections

Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects
A Phase 1b, Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects
Status: Enrolling
Updated:  7/7/2015
UC San Diego Health System - La Jolla
mi
from
San Diego, CA
Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects
A Phase 1b, Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects
Status: Enrolling
Updated: 7/7/2015
UC San Diego Health System - La Jolla
mi
from
San Diego, CA
Click here to add this to my saved trials
Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects
A Phase 1b, Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects
Status: Enrolling
Updated:  7/7/2015
Allergy & Asthma Clinical Research, Inc.
mi
from
Walnut Creek, CA
Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects
A Phase 1b, Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects
Status: Enrolling
Updated: 7/7/2015
Allergy & Asthma Clinical Research, Inc.
mi
from
Walnut Creek, CA
Click here to add this to my saved trials
Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects
A Phase 1b, Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects
Status: Enrolling
Updated:  7/7/2015
University of South Florida Asthma, Allergy or Immunology Clinical Research Unit
mi
from
Tampa, FL
Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects
A Phase 1b, Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects
Status: Enrolling
Updated: 7/7/2015
University of South Florida Asthma, Allergy or Immunology Clinical Research Unit
mi
from
Tampa, FL
Click here to add this to my saved trials
Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects
A Phase 1b, Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects
Status: Enrolling
Updated:  7/7/2015
Institute for Asthma and Allergy, P.C.
mi
from
Chevy Chase, MD
Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects
A Phase 1b, Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects
Status: Enrolling
Updated: 7/7/2015
Institute for Asthma and Allergy, P.C.
mi
from
Chevy Chase, MD
Click here to add this to my saved trials
Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects
A Phase 1b, Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects
Status: Enrolling
Updated:  7/7/2015
Massachusetts General Hospital Allergy Associates
mi
from
Boston, MA
Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects
A Phase 1b, Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects
Status: Enrolling
Updated: 7/7/2015
Massachusetts General Hospital Allergy Associates
mi
from
Boston, MA
Click here to add this to my saved trials
Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects
A Phase 1b, Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects
Status: Enrolling
Updated:  7/7/2015
Winthrop University Hospital Clinical Trials Center
mi
from
Mineola, NY
Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects
A Phase 1b, Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects
Status: Enrolling
Updated: 7/7/2015
Winthrop University Hospital Clinical Trials Center
mi
from
Mineola, NY
Click here to add this to my saved trials
Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects
A Phase 1b, Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects
Status: Enrolling
Updated:  7/7/2015
Icahn School of Medicine at Mount Sinai - The Mount Sinai Medical Center
mi
from
New York, NY
Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects
A Phase 1b, Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects
Status: Enrolling
Updated: 7/7/2015
Icahn School of Medicine at Mount Sinai - The Mount Sinai Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects
A Phase 1b, Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects
Status: Enrolling
Updated:  7/7/2015
UC Physicians Company
mi
from
Cincinnati, OH
Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects
A Phase 1b, Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects
Status: Enrolling
Updated: 7/7/2015
UC Physicians Company
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects
A Phase 1b, Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects
Status: Enrolling
Updated:  7/7/2015
Baker Allergy, Asthma and Dermatology Research Center
mi
from
Lake Oswego, OR
Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects
A Phase 1b, Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects
Status: Enrolling
Updated: 7/7/2015
Baker Allergy, Asthma and Dermatology Research Center
mi
from
Lake Oswego, OR
Click here to add this to my saved trials
Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects
A Phase 1b, Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects
Status: Enrolling
Updated:  7/7/2015
AARA Research Center
mi
from
Dallas, TX
Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects
A Phase 1b, Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects
Status: Enrolling
Updated: 7/7/2015
AARA Research Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects
A Phase 1b, Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects
Status: Enrolling
Updated:  7/7/2015
Washington University School of Medicine
mi
from
St. Louis, MO
Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects
A Phase 1b, Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects
Status: Enrolling
Updated: 7/7/2015
Washington University School of Medicine
mi
from
St. Louis, MO
Click here to add this to my saved trials
Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects
A Phase 1b, Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects
Status: Enrolling
Updated:  7/7/2015
Penn State Hershey Medical Center
mi
from
Hershey, PA
Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects
A Phase 1b, Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects
Status: Enrolling
Updated: 7/7/2015
Penn State Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects
A Phase 1b, Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects
Status: Enrolling
Updated:  7/7/2015
Ospedale L. Sacco
mi
from
Milano,
Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects
A Phase 1b, Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects
Status: Enrolling
Updated: 7/7/2015
Ospedale L. Sacco
mi
from
Milano,
Click here to add this to my saved trials
Treatment of Staphylococcus Aureus Colonization in Hand Eczema
An Investigator-Initiated Study: Treatment of Staphylococcus Aureus Colonization in Hand Eczema Decreases Severity of Disease
Status: Enrolling
Updated:  7/8/2015
Mount Sinai School of Medicine
mi
from
New York, NY
Treatment of Staphylococcus Aureus Colonization in Hand Eczema
An Investigator-Initiated Study: Treatment of Staphylococcus Aureus Colonization in Hand Eczema Decreases Severity of Disease
Status: Enrolling
Updated: 7/8/2015
Mount Sinai School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
UVA1 Light for Treatment of Scleroderma and Similar Conditions
The Effectiveness Of UVA1 Irradiation In The Treatment Of Skin Conditions With Altered Dermal Matrix: A Controlled, Cross-Over Study
Status: Enrolling
Updated:  7/8/2015
University of Michigan Department of Dermatology
mi
from
Ann Arbor, MI
UVA1 Light for Treatment of Scleroderma and Similar Conditions
The Effectiveness Of UVA1 Irradiation In The Treatment Of Skin Conditions With Altered Dermal Matrix: A Controlled, Cross-Over Study
Status: Enrolling
Updated: 7/8/2015
University of Michigan Department of Dermatology
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Imaging of Soft Tissues
Elasticity Imaging of Soft Tissues
Status: Enrolling
Updated:  7/9/2015
University of Michigan Hospital
mi
from
Ann Arbor, MI
Imaging of Soft Tissues
Elasticity Imaging of Soft Tissues
Status: Enrolling
Updated: 7/9/2015
University of Michigan Hospital
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
ADRN Barrier/Immunoprofiling Exploratory Pilot Study
ADRN Barrier/Immunoprofiling Exploratory Pilot Study (ADRN-04)
Status: Enrolling
Updated:  7/23/2015
National Jewish Health
mi
from
Denver, CO
ADRN Barrier/Immunoprofiling Exploratory Pilot Study
ADRN Barrier/Immunoprofiling Exploratory Pilot Study (ADRN-04)
Status: Enrolling
Updated: 7/23/2015
National Jewish Health
mi
from
Denver, CO
Click here to add this to my saved trials
ADRN Barrier/Immunoprofiling Exploratory Pilot Study
ADRN Barrier/Immunoprofiling Exploratory Pilot Study (ADRN-04)
Status: Enrolling
Updated:  7/23/2015
University of Rochester
mi
from
Rochester, NY
ADRN Barrier/Immunoprofiling Exploratory Pilot Study
ADRN Barrier/Immunoprofiling Exploratory Pilot Study (ADRN-04)
Status: Enrolling
Updated: 7/23/2015
University of Rochester
mi
from
Rochester, NY
Click here to add this to my saved trials
ADRN Barrier/Immunoprofiling Exploratory Pilot Study
ADRN Barrier/Immunoprofiling Exploratory Pilot Study (ADRN-04)
Status: Enrolling
Updated:  7/23/2015
Oregon Health and Science University
mi
from
Portland, OR
ADRN Barrier/Immunoprofiling Exploratory Pilot Study
ADRN Barrier/Immunoprofiling Exploratory Pilot Study (ADRN-04)
Status: Enrolling
Updated: 7/23/2015
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
UVA1 Light for Scleroderma and Similar Conditions
The Effectiveness of UVA1 Irradiation in the Treatment of Skin Conditions With Altered Dermal Matrix: An Open Pilot Study
Status: Enrolling
Updated:  7/24/2015
University of Michigan Department of Dermatology
mi
from
Ann Arbor, MI
UVA1 Light for Scleroderma and Similar Conditions
The Effectiveness of UVA1 Irradiation in the Treatment of Skin Conditions With Altered Dermal Matrix: An Open Pilot Study
Status: Enrolling
Updated: 7/24/2015
University of Michigan Department of Dermatology
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
A Phase III Randomized, Double-blind, Placebo-controlled Study With an Open-label Extension Evaluating the Efficacy, Safety and Immunogenicity of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks of Angioedema in Patients With HAE
Status: Enrolling
Updated:  8/3/2015
Allergy, Asthma & Immunology, Assoc, Ltd.
mi
from
Scottsdale, AZ
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
A Phase III Randomized, Double-blind, Placebo-controlled Study With an Open-label Extension Evaluating the Efficacy, Safety and Immunogenicity of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks of Angioedema in Patients With HAE
Status: Enrolling
Updated: 8/3/2015
Allergy, Asthma & Immunology, Assoc, Ltd.
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
A Phase III Randomized, Double-blind, Placebo-controlled Study With an Open-label Extension Evaluating the Efficacy, Safety and Immunogenicity of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks of Angioedema in Patients With HAE
Status: Enrolling
Updated:  8/3/2015
Allergy & Asthma Institute of the Valley
mi
from
Granada Hills, CA
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
A Phase III Randomized, Double-blind, Placebo-controlled Study With an Open-label Extension Evaluating the Efficacy, Safety and Immunogenicity of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks of Angioedema in Patients With HAE
Status: Enrolling
Updated: 8/3/2015
Allergy & Asthma Institute of the Valley
mi
from
Granada Hills, CA
Click here to add this to my saved trials
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
A Phase III Randomized, Double-blind, Placebo-controlled Study With an Open-label Extension Evaluating the Efficacy, Safety and Immunogenicity of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks of Angioedema in Patients With HAE
Status: Enrolling
Updated:  8/3/2015
UCLA Department of Medicine Division of Clinical Immunology, David Geffen School of Medicine
mi
from
Los Angeles, CA
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
A Phase III Randomized, Double-blind, Placebo-controlled Study With an Open-label Extension Evaluating the Efficacy, Safety and Immunogenicity of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks of Angioedema in Patients With HAE
Status: Enrolling
Updated: 8/3/2015
UCLA Department of Medicine Division of Clinical Immunology, David Geffen School of Medicine
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
A Phase III Randomized, Double-blind, Placebo-controlled Study With an Open-label Extension Evaluating the Efficacy, Safety and Immunogenicity of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks of Angioedema in Patients With HAE
Status: Enrolling
Updated:  8/3/2015
USF Asthma, Allergy and Immunology Clinical Research Unit
mi
from
Tampa, FL
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
A Phase III Randomized, Double-blind, Placebo-controlled Study With an Open-label Extension Evaluating the Efficacy, Safety and Immunogenicity of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks of Angioedema in Patients With HAE
Status: Enrolling
Updated: 8/3/2015
USF Asthma, Allergy and Immunology Clinical Research Unit
mi
from
Tampa, FL
Click here to add this to my saved trials
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
A Phase III Randomized, Double-blind, Placebo-controlled Study With an Open-label Extension Evaluating the Efficacy, Safety and Immunogenicity of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks of Angioedema in Patients With HAE
Status: Enrolling
Updated:  8/3/2015
Family Allergy and Asthma Center
mi
from
Atlanta, GA
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
A Phase III Randomized, Double-blind, Placebo-controlled Study With an Open-label Extension Evaluating the Efficacy, Safety and Immunogenicity of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks of Angioedema in Patients With HAE
Status: Enrolling
Updated: 8/3/2015
Family Allergy and Asthma Center
mi
from
Atlanta, GA
Click here to add this to my saved trials
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
A Phase III Randomized, Double-blind, Placebo-controlled Study With an Open-label Extension Evaluating the Efficacy, Safety and Immunogenicity of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks of Angioedema in Patients With HAE
Status: Enrolling
Updated:  8/3/2015
Institute for Asthma and Allergy, P.C.
mi
from
Chevy Chase, MD
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
A Phase III Randomized, Double-blind, Placebo-controlled Study With an Open-label Extension Evaluating the Efficacy, Safety and Immunogenicity of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks of Angioedema in Patients With HAE
Status: Enrolling
Updated: 8/3/2015
Institute for Asthma and Allergy, P.C.
mi
from
Chevy Chase, MD
Click here to add this to my saved trials
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
A Phase III Randomized, Double-blind, Placebo-controlled Study With an Open-label Extension Evaluating the Efficacy, Safety and Immunogenicity of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks of Angioedema in Patients With HAE
Status: Enrolling
Updated:  8/3/2015
Asthma & Allergy Center - Washington University School of Medicine
mi
from
St. Louis, MO
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
A Phase III Randomized, Double-blind, Placebo-controlled Study With an Open-label Extension Evaluating the Efficacy, Safety and Immunogenicity of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks of Angioedema in Patients With HAE
Status: Enrolling
Updated: 8/3/2015
Asthma & Allergy Center - Washington University School of Medicine
mi
from
St. Louis, MO
Click here to add this to my saved trials
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
A Phase III Randomized, Double-blind, Placebo-controlled Study With an Open-label Extension Evaluating the Efficacy, Safety and Immunogenicity of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks of Angioedema in Patients With HAE
Status: Enrolling
Updated:  8/3/2015
Optimed Research, LTD
mi
from
Columbus, OH
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
A Phase III Randomized, Double-blind, Placebo-controlled Study With an Open-label Extension Evaluating the Efficacy, Safety and Immunogenicity of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks of Angioedema in Patients With HAE
Status: Enrolling
Updated: 8/3/2015
Optimed Research, LTD
mi
from
Columbus, OH
Click here to add this to my saved trials
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
A Phase III Randomized, Double-blind, Placebo-controlled Study With an Open-label Extension Evaluating the Efficacy, Safety and Immunogenicity of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks of Angioedema in Patients With HAE
Status: Enrolling
Updated:  8/3/2015
Baker Allergy, Asthma and Dermatology Research Center
mi
from
Lake Oswego, OR
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
A Phase III Randomized, Double-blind, Placebo-controlled Study With an Open-label Extension Evaluating the Efficacy, Safety and Immunogenicity of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks of Angioedema in Patients With HAE
Status: Enrolling
Updated: 8/3/2015
Baker Allergy, Asthma and Dermatology Research Center
mi
from
Lake Oswego, OR
Click here to add this to my saved trials
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
A Phase III Randomized, Double-blind, Placebo-controlled Study With an Open-label Extension Evaluating the Efficacy, Safety and Immunogenicity of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks of Angioedema in Patients With HAE
Status: Enrolling
Updated:  8/3/2015
Pennsylvania State- Milton S. Hershey Medical Center
mi
from
Hershey, PA
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
A Phase III Randomized, Double-blind, Placebo-controlled Study With an Open-label Extension Evaluating the Efficacy, Safety and Immunogenicity of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks of Angioedema in Patients With HAE
Status: Enrolling
Updated: 8/3/2015
Pennsylvania State- Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
A Phase III Randomized, Double-blind, Placebo-controlled Study With an Open-label Extension Evaluating the Efficacy, Safety and Immunogenicity of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks of Angioedema in Patients With HAE
Status: Enrolling
Updated:  8/3/2015
AARA Research Center
mi
from
Dallas, TX
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
A Phase III Randomized, Double-blind, Placebo-controlled Study With an Open-label Extension Evaluating the Efficacy, Safety and Immunogenicity of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks of Angioedema in Patients With HAE
Status: Enrolling
Updated: 8/3/2015
AARA Research Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
A Phase III Randomized, Double-blind, Placebo-controlled Study With an Open-label Extension Evaluating the Efficacy, Safety and Immunogenicity of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks of Angioedema in Patients With HAE
Status: Enrolling
Updated:  8/3/2015
University of Texas Medical Branch
mi
from
Galveston, TX
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
A Phase III Randomized, Double-blind, Placebo-controlled Study With an Open-label Extension Evaluating the Efficacy, Safety and Immunogenicity of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks of Angioedema in Patients With HAE
Status: Enrolling
Updated: 8/3/2015
University of Texas Medical Branch
mi
from
Galveston, TX
Click here to add this to my saved trials
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
A Phase III Randomized, Double-blind, Placebo-controlled Study With an Open-label Extension Evaluating the Efficacy, Safety and Immunogenicity of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks of Angioedema in Patients With HAE
Status: Enrolling
Updated:  8/3/2015
Allergy, Asthma & Immunology Clinic, P.A.
mi
from
Irving, TX
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
A Phase III Randomized, Double-blind, Placebo-controlled Study With an Open-label Extension Evaluating the Efficacy, Safety and Immunogenicity of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks of Angioedema in Patients With HAE
Status: Enrolling
Updated: 8/3/2015
Allergy, Asthma & Immunology Clinic, P.A.
mi
from
Irving, TX
Click here to add this to my saved trials
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
A Phase III Randomized, Double-blind, Placebo-controlled Study With an Open-label Extension Evaluating the Efficacy, Safety and Immunogenicity of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks of Angioedema in Patients With HAE
Status: Enrolling
Updated:  8/3/2015
Marycliff Allergy Specialists
mi
from
Spokane, WA
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
A Phase III Randomized, Double-blind, Placebo-controlled Study With an Open-label Extension Evaluating the Efficacy, Safety and Immunogenicity of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks of Angioedema in Patients With HAE
Status: Enrolling
Updated: 8/3/2015
Marycliff Allergy Specialists
mi
from
Spokane, WA
Click here to add this to my saved trials
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
A Phase III Randomized, Double-blind, Placebo-controlled Study With an Open-label Extension Evaluating the Efficacy, Safety and Immunogenicity of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks of Angioedema in Patients With HAE
Status: Enrolling
Updated:  8/3/2015
University of Cincinnati Physicians, Inc
mi
from
Cincinnati, OH
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
A Phase III Randomized, Double-blind, Placebo-controlled Study With an Open-label Extension Evaluating the Efficacy, Safety and Immunogenicity of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks of Angioedema in Patients With HAE
Status: Enrolling
Updated: 8/3/2015
University of Cincinnati Physicians, Inc
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
A Phase III Randomized, Double-blind, Placebo-controlled Study With an Open-label Extension Evaluating the Efficacy, Safety and Immunogenicity of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks of Angioedema in Patients With HAE
Status: Enrolling
Updated:  8/3/2015
UMHAT "Tsaritsa Yoanna - ISUL"; Clinic of Ear-Nose-Throat Diseases
mi
from
Sofia,
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
A Phase III Randomized, Double-blind, Placebo-controlled Study With an Open-label Extension Evaluating the Efficacy, Safety and Immunogenicity of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks of Angioedema in Patients With HAE
Status: Enrolling
Updated: 8/3/2015
UMHAT "Tsaritsa Yoanna - ISUL"; Clinic of Ear-Nose-Throat Diseases
mi
from
Sofia,
Click here to add this to my saved trials
Optical Biopsy of Human Skin in Conjunction With Laser Treatment
Optical Biopsy of Human Skin in Conjunction With Laser Treatment
Status: Enrolling
Updated:  8/5/2015
Beckman Laser Institute, Unversity of California Irvine
mi
from
Irvine, CA
Optical Biopsy of Human Skin in Conjunction With Laser Treatment
Optical Biopsy of Human Skin in Conjunction With Laser Treatment
Status: Enrolling
Updated: 8/5/2015
Beckman Laser Institute, Unversity of California Irvine
mi
from
Irvine, CA
Click here to add this to my saved trials
N-Acetyl Cysteine in Pathologic Skin Picking
A Double-Blind, Placebo-Controlled Study of N-Acetyl Cysteine in Pathologic Skin Picking
Status: Enrolling
Updated:  8/14/2015
University of Chicago
mi
from
Chicago, IL
N-Acetyl Cysteine in Pathologic Skin Picking
A Double-Blind, Placebo-Controlled Study of N-Acetyl Cysteine in Pathologic Skin Picking
Status: Enrolling
Updated: 8/14/2015
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Pilot Study of Incidence and Change in Existing Pressure Ulcers: TC500 Bed Compared With Standard Beds
A Pilot Study of Pressure Ulcer Incidence and Change in Existing Pressure Ulcers Comparing Subjects Placed on the TC500 Bed With Standard Beds in the 850-SICU Unit
Status: Enrolling
Updated:  8/25/2015
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Pilot Study of Incidence and Change in Existing Pressure Ulcers: TC500 Bed Compared With Standard Beds
A Pilot Study of Pressure Ulcer Incidence and Change in Existing Pressure Ulcers Comparing Subjects Placed on the TC500 Bed With Standard Beds in the 850-SICU Unit
Status: Enrolling
Updated: 8/25/2015
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Click here to add this to my saved trials
Safety Study of Rituximab (Rituxan®) in Chronic Urticaria
Phase I/II Open Label Evaluation of the Safety and Efficacy of Rituximab in Patients With Chronic Urticaria (The Rituximab Urticaria Study - "RUSTY")
Status: Enrolling
Updated:  8/31/2015
Johns Hopkins University/Bayview Medical Center
mi
from
Baltimore, MD
Safety Study of Rituximab (Rituxan®) in Chronic Urticaria
Phase I/II Open Label Evaluation of the Safety and Efficacy of Rituximab in Patients With Chronic Urticaria (The Rituximab Urticaria Study - "RUSTY")
Status: Enrolling
Updated: 8/31/2015
Johns Hopkins University/Bayview Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Evaluation of 3 Versus 10 Days of Antibiotics in Skin Abscesses After Surgical Drainage
Randomized Non-inferiority Trial of 3 Versus 10 Days of Trimethoprim-Sulfamethoxazole in Community-Associated Skin Abscesses After Surgical Drainage
Status: Enrolling
Updated:  9/17/2015
Women and Children's Hospital of Buffalo
mi
from
Buffalo, NY
Evaluation of 3 Versus 10 Days of Antibiotics in Skin Abscesses After Surgical Drainage
Randomized Non-inferiority Trial of 3 Versus 10 Days of Trimethoprim-Sulfamethoxazole in Community-Associated Skin Abscesses After Surgical Drainage
Status: Enrolling
Updated: 9/17/2015
Women and Children's Hospital of Buffalo
mi
from
Buffalo, NY
Click here to add this to my saved trials
Structure of the Herpes Simplex Virus Receptor
Polymorphism of the Herpes Simplex Virus Receptor
Status: Enrolling
Updated:  9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Structure of the Herpes Simplex Virus Receptor
Polymorphism of the Herpes Simplex Virus Receptor
Status: Enrolling
Updated: 9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Pharmacogenetics of Ace Inhibitor-Associated Angioedema
Pharmacogenetics of Ace Inhibitor-Associated Angioedema:Aim 1
Status: Enrolling
Updated:  10/5/2015
Vanderbilt University- General Clinic Research Center
mi
from
Nashville, TN
Pharmacogenetics of Ace Inhibitor-Associated Angioedema
Pharmacogenetics of Ace Inhibitor-Associated Angioedema:Aim 1
Status: Enrolling
Updated: 10/5/2015
Vanderbilt University- General Clinic Research Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS)
Infliximab Therapy to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis
Status: Enrolling
Updated:  11/3/2015
Massachusetts Eye & Ear Infirmary
mi
from
Boston, MA
Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS)
Infliximab Therapy to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis
Status: Enrolling
Updated: 11/3/2015
Massachusetts Eye & Ear Infirmary
mi
from
Boston, MA
Click here to add this to my saved trials
P400 for Stage II-IV Pressure Ulcers in Home and Extended Care
Assessment of the Incidence and Treatment of Stage II -IV Pressure Ulcers in the Home Care or Extended Care Environments Utilizing the P400 Mattress
Status: Enrolling
Updated:  11/16/2015
Southwest Regional Wound Care Center
mi
from
Lubbock, TX
P400 for Stage II-IV Pressure Ulcers in Home and Extended Care
Assessment of the Incidence and Treatment of Stage II -IV Pressure Ulcers in the Home Care or Extended Care Environments Utilizing the P400 Mattress
Status: Enrolling
Updated: 11/16/2015
Southwest Regional Wound Care Center
mi
from
Lubbock, TX
Click here to add this to my saved trials
Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections
A Phase III, Multicentre, Randomised, Double-Blind Comparative Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil (600 mg Every 8 Hours) Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Complicated Bacterial Skin and Soft Tissue Infections With Evidence of Systemic Inflammatory Response or Underlying Comorbidities
Status: Enrolling
Updated:  11/18/2015
Clinical Research Facility
mi
from
Chula Vista, CA
Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections
A Phase III, Multicentre, Randomised, Double-Blind Comparative Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil (600 mg Every 8 Hours) Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Complicated Bacterial Skin and Soft Tissue Infections With Evidence of Systemic Inflammatory Response or Underlying Comorbidities
Status: Enrolling
Updated: 11/18/2015
Clinical Research Facility
mi
from
Chula Vista, CA
Click here to add this to my saved trials
Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections
A Phase III, Multicentre, Randomised, Double-Blind Comparative Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil (600 mg Every 8 Hours) Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Complicated Bacterial Skin and Soft Tissue Infections With Evidence of Systemic Inflammatory Response or Underlying Comorbidities
Status: Enrolling
Updated:  11/18/2015
Clinical Research Facility
mi
from
Orlando, FL
Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections
A Phase III, Multicentre, Randomised, Double-Blind Comparative Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil (600 mg Every 8 Hours) Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Complicated Bacterial Skin and Soft Tissue Infections With Evidence of Systemic Inflammatory Response or Underlying Comorbidities
Status: Enrolling
Updated: 11/18/2015
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections
A Phase III, Multicentre, Randomised, Double-Blind Comparative Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil (600 mg Every 8 Hours) Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Complicated Bacterial Skin and Soft Tissue Infections With Evidence of Systemic Inflammatory Response or Underlying Comorbidities
Status: Enrolling
Updated:  11/18/2015
Clinical Research Facility
mi
from
West Palm Beach, FL
Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections
A Phase III, Multicentre, Randomised, Double-Blind Comparative Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil (600 mg Every 8 Hours) Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Complicated Bacterial Skin and Soft Tissue Infections With Evidence of Systemic Inflammatory Response or Underlying Comorbidities
Status: Enrolling
Updated: 11/18/2015
Clinical Research Facility
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections
A Phase III, Multicentre, Randomised, Double-Blind Comparative Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil (600 mg Every 8 Hours) Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Complicated Bacterial Skin and Soft Tissue Infections With Evidence of Systemic Inflammatory Response or Underlying Comorbidities
Status: Enrolling
Updated:  11/18/2015
Clinical Research Facility
mi
from
Carmel, IN
Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections
A Phase III, Multicentre, Randomised, Double-Blind Comparative Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil (600 mg Every 8 Hours) Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Complicated Bacterial Skin and Soft Tissue Infections With Evidence of Systemic Inflammatory Response or Underlying Comorbidities
Status: Enrolling
Updated: 11/18/2015
Clinical Research Facility
mi
from
Carmel, IN
Click here to add this to my saved trials
Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections
A Phase III, Multicentre, Randomised, Double-Blind Comparative Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil (600 mg Every 8 Hours) Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Complicated Bacterial Skin and Soft Tissue Infections With Evidence of Systemic Inflammatory Response or Underlying Comorbidities
Status: Enrolling
Updated:  11/18/2015
Clinical Research Facility
mi
from
Hazard, KY
Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections
A Phase III, Multicentre, Randomised, Double-Blind Comparative Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil (600 mg Every 8 Hours) Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Complicated Bacterial Skin and Soft Tissue Infections With Evidence of Systemic Inflammatory Response or Underlying Comorbidities
Status: Enrolling
Updated: 11/18/2015
Clinical Research Facility
mi
from
Hazard, KY
Click here to add this to my saved trials